Balyasny Asset Management LLC Eye Point Pharmaceuticals, Inc. Transaction History
Balyasny Asset Management LLC
- $63.6 Billion
- Q4 2024
A detailed history of Balyasny Asset Management LLC transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 223,641 shares of EYPT stock, worth $1.36 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
223,641
Previous 67,073
233.43%
Holding current value
$1.36 Million
Previous $535,000
211.4%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding EYPT
# of Institutions
156Shares Held
72.4MCall Options Held
187KPut Options Held
225K-
Cormorant Asset Management, LP Boston, MA8.33MShares$50.6 Million4.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.78MShares$41.2 Million2.1% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.75MShares$35 Million0.08% of portfolio
-
Franklin Resources Inc San Mateo, CA4.14MShares$25.2 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.8MShares$23.1 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $207M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...